Careers Media center Contacts

Arterium launches new hepatotherapeutic drug Hepametion

Arterium launches new hepatotherapeutic drug Hepametion

14 September 2017 | News

Arterium Corporation* presents Hepametion – a new drug for the treatment of liver conditions. It is used in the therapy of the diseases accompanied by intrahepatic cholestasis. Hepametion effectively treats intrahepatic cholestasis in adults, including the patients with chronic hepatitis of various aetiologies and cirrhosis of the liver, intrahepatic cholestasis in pregnant women, and depressive syndrome.

According to WHO, the incidence of liver diseases has increased over the past two decades, resulting in higher mortality. The rise is due to liver diseases and metabolic syndrome becoming more common on the back of hectic life rhythm, bad dietary habits, alcohol abuse, other diseases and lengthy continuous medication related to them.

The advantage of Hepametion is in its lower price as compared to the original drug – it will enable effective treatment for more patients having a serious pathology. The drug's active pharmaceutical ingredient is sourced from a European manufacturer. The drug is available in the form of lyophilisate for solution (dose – 400 mg) with a solvent.

This information is intended for medical and pharmaceutical personnel only and shall be used exclusively in relevant professional activities. The data given here is abridged. For full information about the medicinal product, refer to its instructions for medical use. This website is a specialised publication intended for medical and pharmaceutical personnel only.

 

 

Media gallery
PRESS KIT

Here you can find general information about the company intended for journalists and other stakeholders

MEDIA CONTACTS

For all media-related enquiries,
please contact us
e-mail: pr@arterium.ua
mob.: +38093 124 87 26